Beneficial Ownership Report · SCHEDULE 13G/A
Crescent Biopharma, Inc.
CBIONASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Crescent Biopharma, Inc.
- Company CIK
- 0001253689
- Street
- 300 Fifth Avenue
- City
- Waltham
- State / country code
- MA
- Postal code
- 20850
Statement details
- Amendment number
- 2
- Security class
- Ordinary Shares, $0.001 par value per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Venrock Healthcare Capital Partners III, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 2,228,641.00
- Percent of class
- 5.9
- Sole voting power
- 0.00
- Shared voting power
- 2,228,641.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,228,641.00
Reporting person 2
- Name
- VHCP Co-Investment Holdings III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 2,228,641.00
- Percent of class
- 5.9
- Sole voting power
- 0.00
- Shared voting power
- 2,228,641.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,228,641.00
Reporting person 3
- Name
- Venrock Healthcare Capital Partners EG, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- a
- Aggregate amount owned
- 2,228,641.00
- Percent of class
- 5.9
- Sole voting power
- 0.00
- Shared voting power
- 2,228,641.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,228,641.00
Reporting person 4
- Name
- VHCP Management III, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 2,228,641.00
- Percent of class
- 5.9
- Sole voting power
- 0.00
- Shared voting power
- 2,228,641.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,228,641.00
Reporting person 5
- Name
- VHCP Management EG, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Group designation
- a
- Aggregate amount owned
- 2,228,641.00
- Percent of class
- 5.9
- Sole voting power
- 0.00
- Shared voting power
- 2,228,641.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,228,641.00
Reporting person 6
- Name
- Nimish Shah
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- a
- Aggregate amount owned
- 2,228,641.00
- Percent of class
- 5.9
- Sole voting power
- 0.00
- Shared voting power
- 2,228,641.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,228,641.00
Reporting person 7
- Name
- Bong Y. Koh
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 2,228,641.00
- Percent of class
- 5.9
- Sole voting power
- 0.00
- Shared voting power
- 2,228,641.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 2,228,641.00
Item 1
Issuer
Crescent Biopharma, Inc.
Principal executive office address
300 Fifth Avenue, Waltham, MA, 20850.
Item 2
Citizenship
All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
Filing person
The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.
Principal business or residence address
New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
Item 3
Not applicable indication
Y
Item 4
Percent of class
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentage of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon the sum of (i) 37,143,940 outstanding ordinary shares as of July 27, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on July 30, 2026 and (ii) 437,554 ordinary shares issued subsequent to July 27, 2026 upon the exercise of Pre-Funded Warrants by the Reporting Persons, and giving effect to Pre-Funded Warrants.
Amount beneficially owned
Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of ordinary shares of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 406,365 ordinary shares and pre-funded warrants (the "Pre-Funded Warrants") immediately exercisable for up to 19,628 ordinary shares held by VHCP III; (ii) 40,647 ordinary shares and Pre-Funded Warrants immediately exercisable for up to 1,964 ordinary shares held by VHCP Co-Investment III and (iii) 1,686,722 ordinary shares and Pre-Funded Warrants immediately exercisable for up to 73,315 ordinary shares held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
Sole voting power
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Shared voting power
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Sole dispositive power
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Shared dispositive power
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24.1 Power of Attorney for Bong Y. Koh (incorporated by reference to Exhibit 24.1 to the Reporting Persons' Schedule 13G filed with the SEC on June 23, 2025). Exhibit 24.2 Power of Attorney for Nimish P. Shah (incorporated by reference to Exhibit 24.2 to the Reporting Persons' Schedule 13G filed with the SEC on June 23, 2025). Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on June 23, 2025).
Signature 1
- Reporting person
- Venrock Healthcare Capital Partners III, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 2
- Reporting person
- VHCP Co-Investment Holdings III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 3
- Reporting person
- Venrock Healthcare Capital Partners EG, L.P.
- Signed
- /s/ Sherman G. Souther
- Title
- By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 4
- Reporting person
- VHCP Management III, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 5
- Reporting person
- VHCP Management EG, LLC
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Authorized Signatory
- Date
- 11/16/2026
Signature 6
- Reporting person
- Nimish Shah
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/16/2026
Signature 7
- Reporting person
- Bong Y. Koh
- Signed
- /s/ Sherman G. Souther
- Title
- By Sherman G. Souther, Attorney-in-fact
- Date
- 11/16/2026
Company context
GlycoMimetics is a late clinical-stage biotechnology company that was previously discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach was based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal was to develop transformative therapies for diseases with high unmet medical need. Learn more at www.glycomimetics.com.